Episode 73 – Oral Semaglutide in Obesity and Enoxaparin for Prevention of Deep Vein Thrombosis
Description
Welcome back Rounds Table Listeners!
We are back today with our Classic Rapid Fire Podcast!
This week, Drs. Mike and John Fralick discuss two recent papers exploring the role of oral semaglutide in patients with obesity and the efficacy of enoxaparin in preventing symptomatic venous thromboembolism in hospitalized older adults. Two papers, here we go!
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial (0:00 – 10:50 ).
- Enoxaparin versus Placebo to Prevent Symptomatic Venous Thromboembolism in Hospitalized Older Adult Medical Patients (10:50 – 18:46 ).
And for the Good Stuff:
Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant) (18:46 – 20:15 ).
Chris Luno (20:15 – 21:37 ).
Questions? Comments? Feedback? We’d love to hear from you! @roundstable
The post Episode 73 – Oral Semaglutide in Obesity and Enoxaparin for Prevention of Deep Vein Thrombosis first appeared on Healthy Debate.
The post Episode 73 – Oral Semaglutide in Obesity and Enoxaparin for Prevention of Deep Vein Thrombosis appeared first on Healthy Debate.
United States
